Stock Events

Stock Events

Abeona Therapeutics 

$6.00
105
+$0.07+1.18% Friday 20:00
+$0.00+0%Friday 20:10After hours

Statistics

Day High
6.02
Day Low
6
52W High
7.65
52W Low
4
Volume
36,484
Avg. Volume
-
Mkt Cap
343.1M
P/E Ratio
7.35
Dividend Yield
-
Dividend
-

Upcoming

Earnings

16NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-0.39
0.31
1.01
1.71
Expected EPS
-0.16
Actual EPS
N/A

Financials

1,223.08%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
5.82MRevenue
71.18MNet Income

Analyst Ratings

20.50Average Price Target
The highest estimate is 21.00.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ABEO. It's not an investment recommendation.
Apple
16
AAPL
NVIDIA
16
NVDA
Alphabet
14
GOOGL
Netflix
14
NFLX

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Biogen
BIIB
Mkt Cap32.28B
Biogen focuses on developing therapies for neurological and neurodegenerative diseases, directly competing with Abeona's gene therapy approach for similar disorders.
Pfizer
PFE
Mkt Cap159.36B
Pfizer has a broad portfolio including gene therapies targeting rare diseases, overlapping with Abeona's focus areas.
Biomarin Pharmaceutical
BMRN
Mkt Cap12.52B
BioMarin Pharmaceutical develops and commercializes innovative biopharmaceuticals for rare diseases, directly competing with Abeona's rare disease focus.
Ultragenyx Pharmaceutical
RARE
Mkt Cap2.52B
Ultragenyx Pharmaceutical targets rare and ultra-rare diseases with its drug development, similar to Abeona's focus.
Sarepta Therapeutics
SRPT
Mkt Cap2.2B
Sarepta Therapeutics focuses on the discovery and development of RNA-based therapeutics and gene therapy for rare diseases, competing with Abeona's gene therapy approach.
Vertex Pharmaceuticals
VRTX
Mkt Cap137.3B
Vertex Pharmaceuticals engages in developing therapies for treating cystic fibrosis and other serious diseases, competing in the rare disease market with Abeona.
Novo Nordisk
NVO
Mkt Cap201.64B
Novo Nordisk focuses on a broad range of treatments including for rare diseases, potentially competing with Abeona in the gene therapy and rare disease market.

About

Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.
Show more...
CEO
Vishwas Seshadri
Employees
226
Country
United States
ISIN
US00289Y2063
WKN
000A3DMHM

Listings

F
DE
PCJ.F
STU
DE
PCJ.STU
STU
DE
PCJP.STU
BOATS
BOATS
ABEO.BOATS

0 Comments

Share your thoughts

FAQ

What is Abeona Therapeutics stock price today?▼
The current price of ABEO is $6.00 USD — it has increased by +1.18% in the past 24 hours. Watch Abeona Therapeutics stock price performance more closely on the chart.
What is Abeona Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Abeona Therapeutics stocks are traded under the ticker ABEO.
Is Abeona Therapeutics stock price growing?▼
ABEO stock has risen by +1.35% compared to the previous week, the month change is a -11.76% fall, over the last year Abeona Therapeutics has showed a -12.92% decrease.
What is Abeona Therapeutics market cap?▼
Today Abeona Therapeutics has the market capitalization of 343.1M
When is the next Abeona Therapeutics earnings date?▼
Abeona Therapeutics is going to release the next earnings report on November 16, 2026.
What were Abeona Therapeutics earnings last quarter?▼
ABEO earnings for the last quarter are -0.35 USD per share, whereas the estimation was -0.23 USD resulting in a -51.08% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Abeona Therapeutics revenue for the last year?▼
Abeona Therapeutics revenue for the last year amounts to 5.82M USD.
What is Abeona Therapeutics net income for the last year?▼
ABEO net income for the last year is 71.18M USD.
How many employees does Abeona Therapeutics have?▼
As of September 05, 2026, the company has 226 employees.
In which sector is Abeona Therapeutics located?▼
Abeona Therapeutics operates in the Health & Wellness sector.
When did Abeona Therapeutics complete a stock split?▼
The last stock split for Abeona Therapeutics was on July 05, 2022 with a ratio of 1:25.
Where is Abeona Therapeutics headquartered?▼
Abeona Therapeutics is headquartered in CLEVELAND, United States.